Quince Therapeutics, Inc.

Quince Therapeutics is a biopharmaceutical company focused on acquiring, developing, and commercializing therapeutics for rare and debilitating diseases. The company's primary pipeline asset is EryDex, a candidate therapy for rare pediatric neurodegenerative conditions, particularly ataxia-telangiectasia (A-T), a rare inherited disorder characterized by neurodegeneration and immunodeficiency caused by mutations in the ATM gene.

The company's proprietary AIDE technology platform represents its core intellectual property. AIDE is a drug-device combination system that uses an automated process to encapsulate therapeutics into patients' own red blood cells. The platform includes the RCL, an automated equipment device, along with associated single-use consumable kits containing medical devices, syringes, and process solutions. This approach aims to leverage patients' own cells as delivery vehicles for treatment.

Quince Therapeutics operates with a small, focused team of 36 full-time employees and is based in South San Francisco, California. The company was incorporated in California in 2012 and previously operated under the name Cortexyme, Inc. before changing its name to Quince Therapeutics in August 2022. The company is listed on Nasdaq.